Cardiol Therapeutics Inc
TSX:CRDL

Watchlist Manager
Cardiol Therapeutics Inc Logo
Cardiol Therapeutics Inc
TSX:CRDL
Watchlist
Price: 1.8 CAD -3.74% Market Closed
Market Cap: 146.9m CAD
Have any thoughts about
Cardiol Therapeutics Inc?
Write Note

Cardiol Therapeutics Inc
Retained Earnings

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Cardiol Therapeutics Inc
Retained Earnings Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Retained Earnings CAGR 3Y CAGR 5Y CAGR 10Y
Cardiol Therapeutics Inc
TSX:CRDL
Retained Earnings
-CA$171.7m
CAGR 3-Years
-33%
CAGR 5-Years
-45%
CAGR 10-Years
N/A
Canopy Growth Corp
TSX:WEED
Retained Earnings
-CA$8.5B
CAGR 3-Years
-33%
CAGR 5-Years
-44%
CAGR 10-Years
-107%
Sundial Growers Inc
NASDAQ:SNDL
Retained Earnings
-CA$1.3B
CAGR 3-Years
-31%
CAGR 5-Years
-71%
CAGR 10-Years
N/A
Cronos Group Inc
TSX:CRON
Retained Earnings
$414m
CAGR 3-Years
-19%
CAGR 5-Years
-18%
CAGR 10-Years
N/A
Mind Medicine (MindMed) Inc
NASDAQ:MNMD
Retained Earnings
-$364.1m
CAGR 3-Years
-57%
CAGR 5-Years
-152%
CAGR 10-Years
-103%
C
Curaleaf Holdings Inc
CNSX:CURA
Retained Earnings
-$1.1B
CAGR 3-Years
-47%
CAGR 5-Years
-323%
CAGR 10-Years
N/A
No Stocks Found

Cardiol Therapeutics Inc
Glance View

Market Cap
146.9m CAD
Industry
Pharmaceuticals

Cardiol Therapeutics, Inc. is a clinical-stage life sciences company focused on developing anti-inflammatory therapies for cardiovascular disease (CVD). The company is headquartered in Oakville, Ontario and currently employs 11 full-time employees. The company went IPO on 2018-12-20. The firm's lead product, CardiolRx, is a pharmaceutically produced oral cannabidiol formulation that is in a Phase II/III study in hospitalized patients testing positive for COVID-19 with a prior history of, or risk factors for, cardiovascular disease. Cardiol has also received clearance from the Food and Drug Administration (FDA) for its investigational new drug (IND) application for a Phase II international trial that investigates the anti-inflammatory and anti- fibrotic properties of CardiolRx in patients with acute myocarditis, which is a common cause of sudden cardiac death in people under 35 years of age. In addition, Cardiol is developing a subcutaneous formulation of CardiolRx and other anti-inflammatory therapies for the treatment of chronic heart failure.

CRDL Intrinsic Value
0.73 CAD
Overvaluation 60%
Intrinsic Value
Price

See Also

What is Cardiol Therapeutics Inc's Retained Earnings?
Retained Earnings
-171.7m CAD

Based on the financial report for Sep 30, 2024, Cardiol Therapeutics Inc's Retained Earnings amounts to -171.7m CAD.

What is Cardiol Therapeutics Inc's Retained Earnings growth rate?
Retained Earnings CAGR 5Y
-45%

Over the last year, the Retained Earnings growth was -31%. The average annual Retained Earnings growth rates for Cardiol Therapeutics Inc have been -33% over the past three years , -45% over the past five years .

Back to Top